64th ASH Annual Meeting and Exposition: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK

Symposia: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, ALL, Hodgkin lymphoma, clinical trials, apoptosis, Translational Research, CLL, Lymphomas, non-Hodgkin lymphoma, LGL, B Cell lymphoma, Plasma Cell Disorders, Combination therapy, Clinical Research, T Cell lymphoma, drug development, Diseases, indolent lymphoma, aggressive lymphoma, Therapies, therapy sequence, Lymphoid Malignancies, Biological Processes

388-390 (Ernest N. Morial Convention Center)

Moderators:

Kerry A. Rogers, MD, Ohio State University Hospital and Francesco Bertoni, MD, Institute of Oncology Research, Faculty of Biomedical Sciences, USI

Disclosures:

No relevant conflicts of interest to declare.

2:00 PM

205

Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

Haya Y. Al-Ansari¹^*, Saira Bashir²^*, Adrienne Cui³^*, Xiangao Huang, PhD^4,5^*, Yang Hu, PhD^4,6^*, Peter Martin, FRCPC, MD, MS^4,7, Olivier Elemento, PhD^4,8^*, Maurizio Di Liberto, PhD^4,9^* and Selina Chen-Kiang, PhD^4,10,11

¹Weill Cornell Medicine-Qatar, Doha, Qatar
²Barnard College of Columbia University, New York, NY
³The Bronx High School of Science, New York
⁴Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY
⁵Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
⁶Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY
⁷Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
⁸Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY
⁹Department of Pathology and Laboratory Medicine, Meyer Cancer Center, Weill-Cornell Medical College, New York, NY
¹⁰Weil Cornell Medicine, Cornell University, New York, NY
¹¹Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Medicine, New York, NY

2:15 PM

206

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, BS¹^*, Bailey Slawin, BS¹^*, Janani Ravikrishnan, PhD², Chaomei Liu³^*, Wanyi Hu⁴^*, Peiyi Zhang, MS⁴^*, Philip A. Thompson, MBBS⁵, William G. Wierda, MD, PhD⁶, Nitin Jain, MD⁷, Guangrong Zheng, PhD⁴^*, Daohong Zhou, MD⁸, Jennifer A. Woyach, MD⁹ and Deepa Sampath, PhD³

¹Department of Hematopoietic Biology & Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
³Department of Hematopoietic Biology & Malignancy, The University of Texas, MD Anderson Cancer Center, Houston, TX
⁴Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL
⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁸Department of Biochemistry & Structural Biology, University of Texas Health at San Antonio, San Antonio, TX
⁹Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH

2:30 PM

207

Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas

Tayla B. Heavican-Foral, PhD¹, Felix Korell, MD²^*, Irene Scarfò, PhD², Harrison Silva²^*, Allen Basanthakumar¹^*, Foster Powers³^*, David M. Weinstock, MD³, Marcela V. Maus, MD² and Birgit Knoechel, MD, PhD⁴

¹Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
²Cancer Center, Massachusetts General Hospital, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

2:45 PM

208

Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib

Shady I. Tantawy, M.D,¹^*, Burcu Aslan, PhD²^*, Lisa S Chen, PhD³^*, Lakesla Iles⁴^*, Philip A. Thompson, MBBS⁵, Nitin Jain, MD⁶, William G. Wierda, MD, PhD⁷ and Varsha Gandhi, PhD⁸

¹MD Anderson cancer Center, Houston, TX
²MD Anderson Cancer Center, HOUSTON, TX
³Department of Experimental Therapeutics, Univ. of Texas MD Anderson Cancer Ctr., Houston, TX
⁴University of Texas M. D. Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, MD Anderson Cancer Center, Houston, TX
⁷The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁸Department of Experimental Therapeutics, Univ. of Texas M.D. Anderson Cancer Center, Houston, TX

3:00 PM

209

Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1⁺/Pre-BCR⁺ ALL Cells

Gaia Gentile¹^*, Teresa Poggio, PhD²^*, Antonella Catalano³^*, Minna Voutilainen⁴^*, Marta Andrade-Martinez⁵^*, Tobias Ma⁶^*, Roman Sankowski, MD⁷^*, Lina Goncarenko⁸^*, Stefan Tholen⁸^*, Kyuho Han, PhD⁹^*, David Morgens¹⁰^*, Marco Prinz, MD¹¹^*, Michael Luebbert, MD¹², Peter Bronsert¹³^*, Michael Bassik, PhD⁹^*, Michael Cleary¹⁴^*, Oliver Schilling⁸^*, Merja Heinäniemi, PhD¹⁵^* and Jesus Duque Afonso, MD¹⁶^*

¹Deparment of Hematology/Oncology, Universityof Freiburg/University of Freiburg Medical Hospital, Freiburg Im Breisgau, Germany
²Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
³University Medical Center Freiburg, Freiburg, DEU
⁴Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland, Kuopio, Finland
⁵Department of Hematology/Oncology/Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany, Freiburg, Germany
⁶Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg Im Breisgau, BW, Germany
⁷Department of Neuropathology, University of Freiburg Medical Center, Freiburg, Germany, Freiburg, Germany
⁸Institute for Molecular Medicine and Cell Research, University of Freiburg Medical Center, Freiburg, Germany, Freiburg, Germany
⁹Department of Genetics, Stanford University, Stanford, CA
¹⁰Department of Genetics, Stanford University, CA, USA, Stanford
¹¹Institute of Neuropathology, University Medical Center Freiburg, Freiburg, Germany
¹²Dept. of Internal Medicine I, University Medical Center Freiburg, Freiburg, Germany
¹³Institute for Surgical Pathology, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany
¹⁴Stanford University Med. Ctr., Stanford, CA
¹⁵Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland
¹⁶Department of Hematology/Oncology/Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany

3:15 PM

210

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL

Neha Bhagwat, PhD¹, Bruce Ruggeri, PhD¹^*, Yang Zhang, PhD¹^*, Yaron Mosesson²^*, Clare Killick-Cole²^*, Veena Jagannathan³^* and Peggy Scherle, PhD¹

¹Research and Development, Prelude Therapeutics, Wilmington, DE
²Champions Oncology, Rockville, MD
³Champions Oncology, Rockville

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

605.O1.6 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK